Atria Investments Inc Has $364,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Atria Investments Inc lowered its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 7.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,101 shares of the medical device company’s stock after selling 855 shares during the quarter. Atria Investments Inc’s holdings in Tandem Diabetes Care were worth $364,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. boosted its holdings in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after buying an additional 535 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Tandem Diabetes Care by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 602,321 shares of the medical device company’s stock valued at $21,696,000 after buying an additional 16,258 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after buying an additional 748 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Tandem Diabetes Care by 163.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after buying an additional 1,101 shares during the period. Finally, US Bancorp DE boosted its holdings in shares of Tandem Diabetes Care by 15.2% in the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company’s stock valued at $1,394,000 after buying an additional 5,108 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Barclays cut their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Robert W. Baird cut their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Royal Bank of Canada cut their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Finally, Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and an average target price of $45.38.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Stock Up 5.4 %

Tandem Diabetes Care stock opened at $19.17 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a 52-week low of $17.64 and a 52-week high of $53.69. The firm has a 50 day moving average price of $31.38 and a two-hundred day moving average price of $34.55. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -9.93 and a beta of 1.45.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.